Oncogenic HRAS activates epithelial-to-mesenchymal transition and confers stemness to p53-deficient urothelial cells to drive muscle invasion of basal subtype carcinomas

Cancer Research

Volumn 75, Issue 10, 2015, Pages 2017-2028

  He, Feng ^a,b   Melamed, Jonathan ^a   Tang, Moon Shong ^a   Huang, Chuanshu ^a   Wu, Xue Ru ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P19; PROTEIN P21; PROTEIN P53; TRANSCRIPTOME; KRAS2 PROTEIN, MOUSE; MATRIX METALLOPROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOMA; CANCER STEM CELL; CARCINOMA IN SITU; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; MUSCLE INVASIVE UROTHELIAL CARCINOMAS OF THE BLADDER; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; UPREGULATION; UROTHELIUM; ANIMAL; BLADDER TUMOR; CELL MOTION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SMOOTH MUSCLE; TUMOR CELL LINE;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MATRIX METALLOPROTEINASES, SECRETED; MICE, KNOCKOUT; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84942934311     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3067     Document Type: Article

References (55)

1. Lotan Y, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, et al. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer ThinkTank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer 2009;115:4096-103.
2. Dancik GM, Theodorescu D. Pharmacogenomics in bladder cancer. Urol Oncol 2014;32:16-22.
3. Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012;62:523-33.
4. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014;25:152-65.
5. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 2014;111:3110-5.
6. Hurst CD, Knowles MA. Molecular subtyping of invasive bladder cancer: time to divide and rule? Cancer Cell 2014;25:135-6.
7. Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, et al. Combination of a novel gene expression signature with a clinical nomo-gram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 2012;18:1323-33.
8. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014;158:929-44.
9. Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV, et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A 2012;109:2078-83.
10. Sjodahl G, Lovgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, et al. Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol 2013;183:681-91.
11. Huang HY, Shariat SF, Sun TT, Lepor H, Shapiro E, Hsieh JT, et al. Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol 2007;38: 1703-13.
12. Livshits G, Lowe SW. Accelerating cancer modeling with RNAi and non-germline genetically engineered mouse models. Cold Spring Harbor protocols 2013;2013.
13. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713-25.
14. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, et al. Focus on bladder cancer. Cancer Cell 2004;6:111-6.
15. Grossman HB. Superficial bladder cancer: decreasing the risk of recurrence. Oncology (Huntingt) 1996;10:1617-24.
16. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 2010;28:401-8.
17. Wu XR, Kong XP, Pellicer A, Kreibich G, Sun TT. Uroplakins in urothelial biology, function, and disease. Kidney Int 2009;75:1153-65.
18. Gandhi D, Molotkov A, Batourina E, Schneider K, Dan H, Reiley M, et al. Retinoid signaling in progenitors controls specificationand regeneration of the urothelium. Dev Cell 2013;26:469-82.
19. Van Batavia J, Yamany T, Molotkov A, Dan H, Mansukhani M, Batourina E, et al. Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol 2014;16:982-91.
20. Shin K, Lim A, Odegaard JI, Honeycutt JD, Kawano S, Hsieh MH, et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat Cell Biol 2014;16:469-78.
21. Wolff EM, Liang G, Jones PA. Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005;2: 502-10.
22. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004;64: 1911-4.
23. Network TCGAR. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.
24. Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, Cordon-Cardo C, et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest 2007;117:314-25.
25. Mo L, Cheng J, Lee EY, Sun TT, Wu XR. Gene deletion in urothelium by specific expression of Cre recombinase. Am J Physiol Renal Physiol 2005; 289:F562-8.
26. He F, Mo L, Zheng XY, Hu C, Lepor H, Lee EY, et al. Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res 2009; 69:9413-21.
27. Rigby CC, Franks LM. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure. Br J Cancer 1970;24:746-54.
28. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001;20:1803-15.
29. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998;12:3008-19.
30. DeGraff DJ, Robinson VL, Shah JB, Brandt WD, Sonpavde G, Kang Y, et al. Current preclinical models for the advancement of translational bladder cancer research. Mol Cancer Ther 2013;12:121-30.
31. Cohen SM, Ohnishi T, Clark NM, He J, Arnold LL. Investigations of rodent urinary bladder carcinogens: collection, processing, and evaluation of urine and bladders. Toxicol Pathol 2007;35:337-47.
32. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 1993;342:469-71.
33. Huang W, Williamson SR, Rao Q, Lopez-Beltran A, Montironi R, Eble JN, et al. Novel markers of squamous differentiation in the urinary bladder. Hum Pathol 2013;44:1989-97.
34. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 2009;106:14016-21.
35. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009;28:335-44.
36. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 2007;185: 191-203.
37. Lopez-Beltran A, Montironi R, Vidal A, Scarpelli M, Cheng L. Urothelial dysplasia of the bladder: diagnostic features and clinical significance. Anal Quant Cytopathol Histopathol 2013;35:121-9.
38. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502:333-9.
39. Ahmad I, Singh LB, Foth M, Morris CA, Taketo MM, Wu XR, et al. K-Ras and beta-cateninmutations cooperate with Fgfr3 mutationsinmicetopromote tumorigenesisintheskin and lung, but notinthe bladder. Dis Model Mech 2011;4:548-55.
40. Cheng J, Huang H, Zhang ZT, Shapiro E, Pellicer A, Sun TT, et al. Over-expression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 2002;62:4157-63.
41. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-73.
42. Tanaka M, Grossman HB. Tumor suppressor genes of bladder cancer and potential for gene therapy. Adv Exp Med Biol 2003;539(Pt A):185-91.
43. Xylinas E, Kluth LA, Lotan Y, Daneshmand S, Rieken M, Karakiewicz PI, et al. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. Urol Oncol 2014;32:230-42.
44. Shirodkar SP, Lokeshwar VB. Potential new urinary markers in the early detection of bladder cancer. Curr Opin Urol 2009;19:488-93.
45. Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011; 29:3443-9.
46. Cheng J, Huang H, Pak J, Shapiro E, Sun TT, Cordon-Cardo C, et al. Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer Res 2003;63: 179-85.
47. Gao J, Huang HY, Pak J, Cheng J, Zhang ZT, Shapiro E, et al. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene 2004;23:687-96.
48. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009;23:675-80.
49. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell 2014;25:272-81.
50. Zhou H, Huang HY, Shapiro E, Lepor H, Huang WC, Mohammadi M, et al. Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies. Carcinogenesis 2012; 33:770-80.
51. Evangelou K, Bartkova J, Kotsinas A, Pateras IS, Liontos M, Velimezi G, et al. The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death Differ 2013; 20:1485-97.
52. Baker NM, Yee Chow H, Chernoff J, Der CJ. Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers. Clin Cancer Res 2014;20:4740-6.
53. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011;192:209-18.
54. Turley EA, Veiseh M, Radisky DC, Bissell MJ. Mechanisms of disease: epithelial-mesenchymal transition-does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol 2008;5:280-90.
55. Ansieau S, Courtois-Cox S, Morel AP, Puisieux A. Failsafe program escape and EMT: a deleterious partnership. Semin Cancer Biol 2011;21:392-6.